Artemis Investment Management LLP Acquires 252,755 Shares of Repligen Corporation $RGEN

Artemis Investment Management LLP lifted its stake in Repligen Corporation (NASDAQ:RGEN) by 207.6% during the third quarter, HoldingsChannel reports. The institutional investor owned 374,482 shares of the biotechnology company’s stock after acquiring an additional 252,755 shares during the period. Artemis Investment Management LLP’s holdings in Repligen were worth $71,987,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RGEN. ABS Investment Management LLC purchased a new position in Repligen during the second quarter valued at approximately $191,016,000. Angeles Wealth Management LLC grew its holdings in shares of Repligen by 6.6% during the 2nd quarter. Angeles Wealth Management LLC now owns 2,757 shares of the biotechnology company’s stock valued at $376,000 after acquiring an additional 170 shares in the last quarter. State of Michigan Retirement System increased its stake in shares of Repligen by 1.6% in the first quarter. State of Michigan Retirement System now owns 12,753 shares of the biotechnology company’s stock worth $1,503,000 after acquiring an additional 200 shares during the last quarter. Everhart Financial Group Inc. raised its holdings in shares of Repligen by 10.6% during the third quarter. Everhart Financial Group Inc. now owns 2,455 shares of the biotechnology company’s stock worth $472,000 after acquiring an additional 236 shares in the last quarter. Finally, Oregon Public Employees Retirement Fund grew its stake in Repligen by 2.8% in the first quarter. Oregon Public Employees Retirement Fund now owns 10,841 shares of the biotechnology company’s stock valued at $1,277,000 after purchasing an additional 300 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on RGEN shares. JPMorgan Chase & Co. raised their price target on Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Wells Fargo & Company boosted their target price on shares of Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, July 30th. Weiss Ratings raised shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 13th. UBS Group reissued a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th. Finally, Zacks Research cut Repligen from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 28th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $173.21.

Repligen Stock Performance

NASDAQ:RGEN traded down $6.34 during trading hours on Thursday, hitting $160.88. 491,567 shares of the company traded hands, compared to its average volume of 1,042,244. The stock has a market capitalization of $9.08 billion, a price-to-earnings ratio of 220.38, a P/E/G ratio of 3.19 and a beta of 1.08. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $198.87. The firm has a 50-day moving average of $172.66 and a 200 day moving average of $142.75. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. During the same period last year, the business posted $0.26 EPS. The business’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, analysts forecast that Repligen Corporation will post 2.06 EPS for the current year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.